99% Чистота против эстрогенного порошка Keoxifene Raloxifene гидрохлорид CAS 82640-04-8

Быстрая деталь:

Ралоксифена гидрохлорид
кличка: Ралоксифен HCl; Кеосифен; Acos 92138
CAS: 82640-04-8
чистота: 99%
MF: C28H28CLNO4S
МВт: 510.04
Внешность: Светло -желтый порошок
Родственные вещества: Pharmaceutical Grade
Место хранения: Затенение, ограниченное сохранение
производитель: Dewael
Время выполнения: 1-2 Дни после получения оплаты
Срок доставки: Продукты ниже 200 кг по воздуху; Более 200 кг по корабля
Срок поставки: Средний 6 Дни по воздуху; 15 Дни по корабля
Применение: Он используется в профилактике остеопороза у женщин в постменопаузе.

Описание:

Ралоксифен (продается как Evista) это пероральный селективный модулятор рецептора эстрогена (Проповедь) Это обладает эстрогенным действием на кости и антиэстрогенные действия на матку и грудь. It is used in the prevention of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.

This drug is different from hormones (including estrogens and progestins). It works by acting like estrogen (as a selective estrogen receptor modulator or SERM) in some parts of the body. Raloxifene helps to preserve bone mass, but it does not affect the breast and uterus like estrogen or relieve symptoms of menopause such as hot flashes.

Evista (Ралоксифена гидрохлорид) is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (Проповедь) and belongs to the benzothiophene class of compounds. The biological actions of Raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (Agonism) and and the blockade of estrogenic pathways in other tissues (Antagonism).

Приложения:

May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents (e. G., bisphosphonates, calcitonin) or in whom such therapies are contraindicated.

Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.

Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial). Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established.

Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 Not indicated for reduction in the risk of noninvasive breast cancer.

Side effect: Raloxifene may infrequently cause serious blood clots to form in the legs, lungs, or eyes. Other reactions experienced include leg swelling/pain, проблемы с дыханием, chest pain, vision changes. Raloxifene is a teratogenic drug, i. e., can cause developmental abnormalities such as birth defects.

COA:

Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 Not indicated for reduction in the risk of noninvasive breast cancer.
Side effect: Raloxifene may infrequently cause serious blood clots to form in the legs, lungs, or eyes. Other reactions experienced include leg swelling/pain, проблемы с дыханием, chest pain, vision changes. Raloxifene is a teratogenic drug, i. e. can cause developmental abnormalities such as birth defects.

———————————————————————————————————————————————————————————————————————————————————————-

Связаться сейчас